ReviewCureus2025
Efficacy and Safety of Stereotactic Radiosurgery in Patients With Large-Volume Meningiomas ≥10 cm³: A Systematic Review and Single-Arm Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large-volume intracranial meningiomas (LVMs) pose significant surgical challenges and are associated with increased morbidity despite advances in neurosurgical techniques. While stereotactic radiosurgery (SRS) is an established treatment for small- to medium-sized meningiomas, its efficacy and safety profile in LVMs (≥10 cm³) remain uncertain. We performed a systematic review and meta-analysis evaluating the efficacy and safety of SRS in patients with LVMs. PubMed, Embase, Web of Science, and Cochrane databases were searched for studies reporting outcomes of SRS in LVMs. Heterogeneity was assessed using the I² statistic, and pooled estimates were calculated using a random-effects model. Fifteen studies comprising 1,093 patients were included, of whom 955 (87%) presented with meningiomas measuring ≥10 cm³. The median follow-up duration across studies was 55 months (range of medians: 22-106 months). The overall tumor control rate was 91.2% (95% CI: 87.7-93.8%). Subgroup analyses demonstrated higher tumor control rates with hypofractionated (94.9%; 95% CI: 90.8-97.2%) compared to single-session (89.0%; 95% CI: 83.6-92.7%) and staged-SRS (82.6%; 95% CI: 68.9-91.1%). Progression-free survival at three and five years was 91.3% (95% CI: 84.6-95.2%) and 90.6% (95% CI: 82.2-95.3%), respectively. Adverse radiation effects occurred in 15.9% (95% CI: 7.8-29.9%), and symptomatic peritumoral edema in 4.7% (95% CI: 1.6-13.1%). In patients with LVMs, SRS is associated with high tumor control rates and an acceptable safety profile. Hypofractionated SRS appears to offer higher tumor control compared to single-session and staged approaches. Further prospective randomized trials are warranted to validate these findings and optimize treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.